Akèy › Kansè Metastatik › Illinois › Chicago
Etid klinik pou Kansè Metastatik nan Chicago, IL
45 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- Mount Sinai Hospital Medical Center, Chicago
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- ak 3 plis
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Chicago Hospital, Chicago
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Ap rekriteFaz 3
- City of Hope, Chicago
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
Ap rekriteFaz 1
- Northwestern University, Chicago
PRE-ISPY Phase I/II Oncology Platform Program
Ap rekriteFaz 1/2
- The University of Chicago Medicine Comprehensive Cancer Center, Chicago
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Illinois Cancer Specialists, Chicago
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
- Illinois Cancer Specialists, Chicago
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Ap rekriteFaz 3
- Research Site, Chicago
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
Ap rekriteFaz 1/2
- University of Chicago, Chicago
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- University of Illinois at Chicago, Chicago
- University of Chicago Medical Center, Chicago
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- City of Hope, Chicago, Chicago
- Northwestern Memorial Hospital, Chicago
- University of Illinois at Chicago, Chicago
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ap rekriteFaz 3
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- The University of Chicago Medicine, Chicago
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago
CREO - Microwave Ablation Feasibility Study
Ap rekrite
- Rush University Medical Center, Chicago
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Ap rekriteFaz 1
- Northwestern University ( Site 0101), Chicago
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- University of Illinois at Chicago, Chicago
- University of Chicago Hospital, Chicago
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Ap rekriteFaz 2
- Northwestern University, Chicago
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Ap rekriteFaz 3
- Northwestern University, Chicago
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
Ap rekriteFaz 1/2
- Northwestern University, Chicago
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- The University of Chicago Medical Center (UCMC), Chicago
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
Ap rekriteFaz 2
- Research Site, Chicago
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Ap rekriteFaz 1
- University of Chicago Comprehensive Cancer Center, Chicago
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Ap rekriteFaz 3
- Research Site, Chicago
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The University of Chicago Medicine, Chicago
A Study of PYX-201 in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Chicago Medicine, Chicago
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- The University of Chicago Medical Center (UCMC), Chicago
REMASTer: REcurrent Brain Metastases After SRS Trial
Ap rekrite
- University of Chicago, Chicago
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Ap rekriteFaz 3
- Northwestern University, Chicago
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Ap rekriteFaz 1
- Context Investigational Site, Chicago
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Ap rekriteFaz 2
- Northwestern University, Chicago
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Ap rekriteFaz 1/2
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Ap rekriteFaz 1/2
- University of Chicago, Chicago
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 3
- University of Illinois Cancer Center, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Ap rekriteFaz 1
- Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Ap rekriteEtid obsèvasyon
- John H Stroger Jr Hospital of Cook County, Chicago
STM-06: POLARIS-POlymetastic Lesion Ablative Radiotherapy With Immunotherapy Study
Ap rekriteFaz 1
- University of Illinois at Chicago, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ap rekriteFaz 3
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Ap rekriteFaz 1
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chicago
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Ap rekriteFaz 1
- University Of Chicago Medicine Comprehensive Cancer Center, Chicago
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Ap rekriteFaz 1
- Northwestern University, Chicago
- University of Illinois, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of Chicago, Chicago
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Ap rekriteFaz 1/2
- Northwestern University, Chicago
Etid Kansè Metastatik nan lòt vil
- Houston, TX104 etid
- New York City, NY93 etid
- Nashville, TN70 etid
- Boston, MA63 etid
- Los Angeles, CA57 etid
- St. Louis, MO54 etid
- Arlington, VA53 etid
- Philadelphia, PA46 etid
- San Antonio, TX44 etid
- Washington, DC43 etid
- Dallas, TX42 etid
- Seattle, WA39 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)51 etid
- Kansè pwostat45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.